Skip to main content

Table 1 Patient characteristics

From: Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial?

Parameter

Total (n = 76)

ueSRT (n = 20)

eSRT (n = 40)

dSRT (n = 16)

P

Age at surgery, years, median (IQR)

65 (61–69)

68 (61–72)

65 (61–69)

64 (57–67)

0.0574a

Initial PSA, ng/mL, median (IQR)

8.7 (6.4–12.6)

9.2 (6.9–12.6)

8.4 (5.9–13.0)

9.3 (7.2–12.9)

0.6684a

Pathological T stage, no. (%):

 T2

37 (49)

9 (45)

21 (53)

7 (44)

0.0834b

 T3a

35 (46)

10 (50)

19 (48)

6 (38)

 

 T3b

4 (5)

1 (5)

0 (0)

3 (19)

 

Pathological GS, no. (%):

 ≤6

12 (16)

3 (15)

6 (15)

3 (19)

0.1533b

 7

49 (64)

16 (80)

26 (65)

7 (44)

 

 ≥8

15 (20)

1 (5)

8 (20)

6 (38)

 

 Gleason pattern 5 (including tertiary 5)

27 (36)

5 (25)

14 (35)

8 (50)

0.2959b

Extraprostatic extension, no. (%)

37 (49)

10 (50)

18 (45)

9 (56)

0.7416b

Lymphovascular invasion, no. (%)

21 (28)

3 (15)

10 (25)

8 (50)

0.0568b

Positive surgical margin, no. (%)

57 (75)

17 (85)

28 (70)

12 (75)

0.4493b

Seminal vesicle invasion, no. (%)

4 (5)

1 (5)

0 (0)

3 (19)

0.0178*b

Perineural invasion, no. (%)

58 (76)

17 (85)

28 (70)

13 (81)

0.3805b

SRT technique, no. (%):

 3DCRT

61 (80)

19 (95)

27 (68)

15 (94)

0.0130*b

 IMRT

15 (20)

1 (5)

13 (33)

1 (6)

 

Total dose, no. (%):

 60–65 Gy

10 (13)

3 (15)

5 (13)

2 (13)

0.9646b

 66 Gy

60 (79)

16 (80)

31 (78)

13 (81)

 

 70 Gy

6 (8)

1 (5)

4 (10)

1 (6)

 

Concomitant ADT, no. (%)

12 (16)

5 (25)

2 (5)

5 (31)

0.0218*b

PSA doubling time, months, median (IQR)

8.4 (4.6–20.1)

–†

12.7 (6.2–25.1)

5.9 (3.5–14.3)

Median follow-up, months (IQR)

70 (48–95)

74 (57–99)

73 (43–83)

58 (41–99)

0.5386a

  1. SRT salvage radiotherapy, ueSRT ultra-early salvage radiotherapy, eSRT early salvage radiotherapy, dSRT delayed salvage radiotherapy, IQR interquartile range, PSA prostate-specific antigen, GS Gleason score, 3DCRT 3-dimensional conformal radiation therapy, IMRT intensity-modulated radiotherapy, ADT androgen deprivation therapy
  2. *Statistically significant; aone-way ANOVA; bPearson’s χ2 test
  3. †In the ueSRT group, PSA doubling time was only calculable in two patients (3.9 and 5.6 months)